While C4 Therapeutics Inc has underperformed by -4.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CCCC fell by -13.23%, with highs and lows ranging from $11.88 to $3.61, whereas the simple moving average fell by -34.35% in the last 200 days.
On December 19, 2024, Wells Fargo Upgraded C4 Therapeutics Inc (NASDAQ: CCCC) to Overweight. A report published by Stephens on November 18, 2024, Initiated its previous ‘Equal-Weight’ rating for CCCC. JP Morgan also Upgraded CCCC shares as ‘Neutral’, setting a target price of $6 on the company’s shares in a report dated January 29, 2024. Stifel December 13, 2023d the rating to Buy on December 13, 2023, and set its price target from $2 to $12. Credit Suisse February 24, 2023d its ‘Underperform’ rating to ‘Neutral’ for CCCC, as published in its report on February 24, 2023. JP Morgan’s report from February 24, 2023 suggests a price prediction of $5 for CCCC shares, giving the stock a ‘Underweight’ rating. JP Morgan also rated the stock as ‘Neutral’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of C4 Therapeutics Inc (CCCC)
Further, the quarter-over-quarter increase in sales is 38.75%, showing a positive trend in the upcoming months.
To gain a thorough understanding of C4 Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -46.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 6.31, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CCCC is recording an average volume of 1.20M. On a monthly basis, the volatility of the stock is set at 9.82%, whereas on a weekly basis, it is put at 9.44%, with a loss of -4.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $15.00, showing growth from the present price of $3.87, which can serve as yet another indication of whether CCCC is worth investing in or should be passed over.
How Do You Analyze C4 Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 19.37%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 83.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CCCC shares are owned by institutional investors to the tune of 83.28% at present.
